TransMedics Group, Inc. (TMDX) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $99.19, but acceptable to hold if already in. Reasons: Concentration risk — Product: OCS Perfusion Sets and OCS Solutions; Concentration risk — Supplier: single facility in Andover, Massachusetts.
TransMedics Group makes the OCS, the only FDA-approved portable multi-organ warm perfusion platform for heart, lung, and liver transplantation, and operates the NOP providing outsourced organ procurement and logistics to U.S. transplant centers. Revenue comes from OCS Perfusion... Read more
Hold if already holding. Not a fresh buy at $99.19, but acceptable to hold if already in. Reasons: Concentration risk — Product: OCS Perfusion Sets and OCS Solutions; Concentration risk — Supplier: single facility in Andover, Massachusetts. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Under M&A bid. Hold for deal completion or sell if spread < 3%. Score 6.3/10, moderate confidence.
Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductOCS Perfusion Sets and OCS Solutions10-K Item 1A: 'Our ability to generate product revenue and remain profitable depends primarily on sales of OCS Perfusion Sets and OCS Solutions'
- HIGHSuppliersingle facility in Andover, Massachusetts10-K Item 1A: 'all of our manufacturing operations are currently conducted at a single facility in Andover, Massachusetts'
Material Events(8-K, last 90d)
- 2026-02-04Item 5.02MEDIUMCCO Tamer Khayal transitioned to SVP International effective Feb 2, 2026; Giovanni Cecere appointed CCO. GC Anil Ranganath transitioning to non-executive role; Matthew Forsyth appointed SVP General Counsel effective March 9, 2026. Clean handoffs for both roles.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $99.19, but acceptable to hold if already in. Reasons: Concentration risk — Product: OCS Perfusion Sets and OCS Solutions; Concentration risk — Supplier: single facility in Andover, Massachusetts. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Under M&A bid. Hold for deal completion or sell if spread < 3%. Target $135.72 (+36.8%), stop $93.13 (−6.5%), A.R:R 3.2:1. Score 6.3/10, moderate confidence.
Take-profit target: $135.72 (+37.4% upside). Target $135.72 (+36.8%), stop $93.13 (−6.5%), A.R:R 3.2:1. Stop-loss: $93.13.
Concentration risk — Product: OCS Perfusion Sets and OCS Solutions; Concentration risk — Supplier: single facility in Andover, Massachusetts; Leverage penalty (D/E 1.1): -0.5.
TransMedics Group, Inc. trades at a P/E of 20.2 (forward 26.8). TrendMatrix value score: 6.4/10. Verdict: Hold.
20 analysts cover TMDX with a consensus score of 4.2/5. Average price target: $156.
What does TransMedics Group, Inc. do?TransMedics Group makes the OCS, the only FDA-approved portable multi-organ warm perfusion platform for heart, lung,...
TransMedics Group makes the OCS, the only FDA-approved portable multi-organ warm perfusion platform for heart, lung, and liver transplantation, and operates the NOP providing outsourced organ procurement and logistics to U.S. transplant centers. Revenue comes from OCS Perfusion Set/Solution sales and NOP service fees; the company earned $190.3M net income in 2025.